Roche: Port Delivery System With Ranibizumab Shows Positive Trial Results In NAMD

Calgary restaurants face uncertain future amid COVID-19 crisis: ‘How far do you let it bleed?’

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

China reports 1 new mainland Covid-19 cases versus 7 a day earlier

SHANGHAI (REUTERS) – China reported one new confirmed coronavirus case in the mainland as of Tuesday (May 26), up from seven a day earlier, the National Health Commission reported.

It also reported 28 new asymptomatic cases – patients who are infected but do not show symptoms – versus 29 a day earlier.

The new confirmed case was an imported one. The 7 reported a day earlier were also all imported.

The total number of cases to date in the mainland stands at 82,993. The death toll remains unchanged at 4,634.

HKEX signs licence deal with MSCI to launch Asia, EM futures and options contracts

May 27 (Reuters) – The operator of the Hong Kong stock exchange said on Wednesday it has signed a licence agreement with global index publisher MSCI to launch Asia and Emerging Markets futures and options contracts.

Under the deal, MSCI will license to Hong Kong Exchanges and Clearing Ltd’s unit, Hong Kong Futures Exchange, a suite of its equity indexes in the regions to initially introduce 37 futures and options contracts based on the indexes. (Reporting by Anushka Trivedi in Bengaluru; Editing by Kim Coghill)

Sanofi : FDA Approves Dupixentas To Treat Moderate-to-severe Atopic Dermatitis

Sanofi (SNYNF,SNY) said that the U.S. Food and Drug Administration approved Dupixent or dupilumab for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dupixent is currently approved in the U.S. and other countries to treat several diseases driven by type 2 inflammation.

Outside of the U.S., Dupixent is approved for specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma in a number of other countries around the world, including the EU and Japan. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP.

De Blasio signs bill capping NYC restaurant delivery-app fees

Mayor Bill de Blasio signed several bills on Tuesday that could temporarily eat into the profits of food-ordering and delivery apps like Grubhub and UberEats.

Starting June 2, the commissions that food-delivery apps can charge Big Apple eateries will be capped at 20 percent — or 15 percent for delivery charges and 5 percent for any other fees. Such apps have been criticized for charging as much as 40 percent in some cases for orders they help generate and deliver.

Grubhub, which owns Seamless, will also be forced to stop charging restaurants fees for telephone orders that did not result in a take-out order. The Chicago firm has come under fire for charging restaurateurs for answering the phone, even when no order was placed, after The Post first reported on the practice last year.

The new laws will remain in effect for 90 days after New York’s state-of-emergency order is lifted.

Grubhub on Wednesday reiterated its previous statement that the commission cap is “arbitrary” and “will not withstand a legal challenge.”

Kathy Griffin Sparks Outrage With Tweet About Giving Donald Trump Deadly “Syringe With Nothing But Air Inside”

On the same day that President Trump decried Twitter tagging his post with a “fact check” link as a violation of free speech, comedian Kathy Griffin also decided to test her protections under the First Amendment.

CNN’s Jake Tapper tweeted a quote from Trump at a White House diabetes event on Tuesday saying, “I don’t use insulin. Should I be?”

Griffin responded, “Syringe with nothing but air inside it would do the trick.”

Such an injection could result in a fatal blood vessel blockage caused by one or more bubbles of air or other gas in the circulatory system, somewhat like the bends in divers.

Reaction was swift, with Twitter users tagging the Secret Service on their replies, and saying “This is a direct threat to the President of the United States.”

Griffin, for her part, was unrepentant. The comedian repeatedly — and very explicitly — responded to those complaining about her tweet.

This is not the first time Griffin has gone after Trump. In 2017, she tweeted an image of herself and what looked like the bloodied head of President Trump.

The president fired back, saying his 11 year old son, Barron, was impacted by the image.

Griffin later apologized for the image saying, “I went too far. I made a mistake, and I was wrong.”

British Land Company FY Underlying Profit Declines – Quick Facts

The British Land Company (BRLAF.PK,BTLCY.PK,BLND.L) reported a pretax loss of 1.1 billion pounds for the year ended 31 March 2020 compared to a loss of 319 million pounds, prior year. Loss per share was 110.0 pence compared to a loss of 30.0 pence. The Group noted that valuation decline led to IFRS loss for the fiscal year period. Underlying profit was 306 million pounds, a decline of 10.0% from previous year. Underlying earnings per share was 32.7 pence compared to 34.9 pence.

Fiscal year revenue declined to 613 million pounds from 904 million pounds, last year. Net rental income was 478 million pounds compared to 532 million pounds.

The value of the retail portfolio declined 26.1% as ongoing structural challenges were exacerbated at the year end valuation date by the early effects of Covid-19. Overall, the portfolio was down 10.1%, for the fiscal year.

Roche: Port Delivery System With Ranibizumab Shows Positive Trial Results In NAMD

Swiss drug maker Roche (RHHBY) announced Wednesday positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab in people living with neovascular or “wet” age-related macular degeneration or nAMD.

Port Delivery System with ranibizumab or PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over a period of months.

The company noted that the Archway trial met its primary endpoint, demonstrating that patients with PDS who received refills every six months achieved visual acuity outcomes equivalent to those receiving monthly ranibizumab 0.5 mg injections.

In Archway, PDS was generally well-tolerated with a favorable benefit-risk profile.

Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said, “For people around the world receiving frequent eye injections for neovascular AMD, this continuous delivery system could greatly reduce their treatment burden.”

The company expects to present detailed Archway results at an upcoming medical meeting and to submit to regulatory authorities across the world.

The Portal study is also investigating the long-term safety and tolerability of PDS for the treatment of nAMD. PDS is also being studied in the Pagoda trial for the treatment of diabetic macular edema or DME, a vision-threatening complication of diabetes.